Last updated: July 18, 2026
DOW PHARMACEUTICAL SCIENCES v. TARO PHARMACEUTICALS U.S.A. (2:14-cv-05079): Litigation Summary, Patent Issues, and Generic Entry Risk
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc. (No. 2:14-cv-05079) is a U.S. patent infringement case tied to a generic-drug launch risk between brand and generic firms. The litigation posture, likely claims, and settlement dynamics determine whether the generic’s path was blocked by injunctions or enabled by licensing, design-arounds, or non-infringement outcomes.
Because the case number alone does not provide the patent list, asserted claims, parties’ counsel, court orders, or final disposition in the record available in this chat, a complete litigation summary and analysis cannot be produced without generating inaccuracies.
What patents were asserted in Dow Pharmaceutical Sciences v. Taro (2:14-cv-05079)?
A litigation summary requires the asserted patent numbers, application-to-issuance chronology, and the specific claim groupings (independent vs. dependent) driving infringement and validity arguments. Those details are not available here.
Which patent families were at issue?
- Active ingredient or drug product family
- Drug form (tablet/capsule/solution) and dosage strength
- Core IP category (formulation, composition, method of use, manufacturing, or device)
What claims were targeted by the generic?
- Infringement theory (literal infringement vs. DOE)
- Claim construction positions
- Validity challenges (novelty, obviousness, §112 enablement/adequate description, indefiniteness)
What was the infringement and validity framework in 2:14-cv-05079?
A legal analysis depends on the operative complaint, answer, and any early motions:
- Motion to dismiss (pleading sufficiency)
- Markman schedule and claim construction outcomes
- Summary judgment rulings
- Daubert or expert testimony rulings
- Preliminary injunction or TRO motion practice (typical in Hatch-Waxman disputes)
Those filings and rulings are not present in the information provided.
How did the court handle claim construction and expert testimony?
Patent infringement outcomes in federal courts often turn on claim construction. A real analysis must cite:
- Claim terms construed
- The court’s Markman order dates
- How construction changed infringement mapping
- Whether experts addressed the construed limitations
No claim construction record is available here.
What orders or milestones shaped the case outcome (injunction, stay, settlement)?
Litigation trajectories typically include:
- Scheduling order and discovery limits
- Court-directed settlement discussions
- Case stay pending PTO reexamination/inter partes review (if pursued)
- Trial start date and dispositive motion deadlines
- Final judgment or dismissal without prejudice
A timeline of those milestones cannot be built without docket text or order listings.
Was this case resolved by settlement, dismissal, or a final merits judgment?
A litigation summary needs the disposition:
- Settlement agreement terms (license scope, royalty structure, launch timing)
- Dismissal type (with/without prejudice)
- Judgment after trial
- Entry of final injunction (if any) and its scope
No disposition data is available in the provided material.
What does the case imply for generic entry timing and FDA risk?
For high-stakes launch planning, the key is whether the case affected:
- 30-month stay status (if tied to an ANDA Paragraph IV)
- Whether FDA approval could proceed while litigation continued
- Whether a licensed entry date was set
- Whether design-around work reduced infringement risk
That FDA-pathway linkage cannot be confirmed without connecting the case to the specific ANDA, Orange Book-listed patents, and the FDA approval or approval dates.
Which company’s product was blocked or enabled by this litigation?
Impact analysis depends on:
- Which party was the NDA holder/Orange Book patent holder vs. the ANDA filer
- Which dosage forms and strengths were covered
- Whether the generic was enjoined or contractually licensed
The necessary product and Orange Book mapping is not available.
How strong is the patent estate suggested by this case posture?
A strength analysis needs:
- Claim survivability after motions
- Validity outcomes
- Whether the asserted patents were narrowed or invalidated
- Whether the generic prevailed on non-infringement for all asserted claims
No motion or ruling record is available.
What patent litigation risk exists for comparable generics in the same therapeutic class?
Transferable risk mapping requires:
- The drug’s relevant chemistry and manufacturing process limitations
- The claim types most commonly enforced (formulation vs. method vs. manufacturing)
- The likelihood of design-around success based on claim scope
Without the asserted patent claims and construction, a comparison cannot be supported.
Key Takeaways
- No accurate, facts-based litigation summary or legal analysis can be produced from case number alone.
- A credible analysis requires the docket-level specifics: asserted patents, claim terms, claim construction, dispositive orders, and final disposition or settlement details.
- Without those record elements, any patent assertions, outcomes, or generic-entry implications would risk being incorrect.
FAQs
- How do I map a district court case number to the specific ANDA and Orange Book patents involved?
- What docket documents are most important for determining whether a Hatch-Waxman dispute ended in settlement versus judgment?
- Which claim types (formulation, method of use, manufacturing) most often drive infringement findings in ANDA litigation?
- How do claim construction rulings change the risk profile for design-arounds in generic litigation?
- What settlement terms most strongly affect launch timing for other ANDA filers in the same drug product?
References
- None.
